Tiziana Sampietro

Dr. Tiziana Sampietro

Toscana Gabriele Monasterio Foundation, Lipoapheresis Unit - Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias, I-56124 Pisa, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
MPMariarita Puntoni
Mariarita Puntoni
FSFrancesco Sbrana
Francesco Sbrana
FBFederico Bigazzi
Federico Bigazzi
TSTiziana Sampietro
Tiziana Sampietro

Verified
Journal Article
Open access
PDF file
MGMaria Francesca Greco
Maria Francesca Greco
Cesare SirtoriCesare Sirtori
Cesare Sirtori
ACAlberto Corsini
Alberto Corsini
Marat EzhovMarat Ezhov
Marat Ezhov
TSTiziana Sampietro
Tiziana Sampietro
Massimiliano RuscicaMassimiliano Ruscica
Massimiliano Ruscica
It is well-known that elevated lipoprotein(a)—Lp(a)—levels are associated with a higher risk of cardiovascular (CV) mortality and all-cause mortality, although a standard pharmacotherapeutic approach is still undefined for patients with high CV risk dependent on hyperlipoproteinemia(a). Combined with high Lp(a) levels, familial hypercholesterolemia (FH) leads to a greater CVD risk. In suspected FH patients, the proportion of cases explained by a rise of Lp(a) levels ranges between 5% and 20%. In the absence of a specific pharmacological approach able to lower Lp(a) to the extent required to achieve CV benefits, the most effective strategy today is lipoprotein apheresis (LA). Although limited, a clear effect on Lp(a) is exerted by PCSK9 antagonists, with apparently different mechanisms when given with statins (raised catabolism) or as monotherapy (reduced production). In the era of RNA-based therapies, a new dawn is represented by the use of antisense oligonucleotides APO(a)Lrx, able to reduce Lp(a) from 35% to over 80%, with generally modest injection site reactions. The improved knowledge of Lp(a) atherogenicity and possible prevention will be of benefit for patients with residual CV risk remaining after the most effective available lipid-lowering agents.

1 October 2018 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
FBFederico Bigazzi
Federico Bigazzi
FSFrancesco Sbrana
Francesco Sbrana
DBDaniele Berretti
Daniele Berretti
ZGZenti Maria Grazia
Zenti Maria Grazia
SZSabina Zambon
Sabina Zambon
TSTiziana Sampietro
Tiziana Sampietro

1 May 2015 in Atherosclerosis Supplements
Verified
Journal Article
Closed access
TSTiziana Sampietro
Tiziana Sampietro
FSF. Sbrana
F. Sbrana
FBF. Bigazzi
F. Bigazzi
ARA. Ripoli
A. Ripoli
BPB. Dal Pino
B. Dal Pino
MPM. Pianelli
M. Pianelli

1 September 2017 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
FSFrancesco Sbrana
Francesco Sbrana
BPBeatrice Dal Pino
Beatrice Dal Pino
FBFederico Bigazzi
Federico Bigazzi
ARAndrea Ripoli
Andrea Ripoli
CPClaudio Passino
Claudio Passino
TSTiziana Sampietro
Tiziana Sampietro
Background: Familial hypercholesterolemia is the elective clinical condition that deserves the maximal personalisation in lipid-lowering therapy, especially in the presence of statin intolerance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising approach to lower low-density lipoprotein (LDL) cholesterol. Methods: We enrolled 18 patients (mean age 62 ± 8 years, 72% men) affected by heterozygous familial hypercholesterolemia and cardiovascular disease, with a history of statin intolerance assigned to PCSK9 inhibitors. Six patients were also on LDL apheresis. Associated Lp(a)-hyperlipoproteinemia (defined as >60 mg/dl) was observed in two out of 18 subjects. PCSK9 inhibitor injectable monoclonal antibodies were administered, every 2 weeks, on top of patient therapy for 12 ± 4 weeks (evolocumab in 15 subjects, alirocumab in three subjects). Results: After 3 months (12 ± 4 weeks) of therapy, a decrease in total cholesterol (–35%), LDL cholesterol (–51%) and Lp(a) levels (–20%) was observed. Five out of 18 patients reached LDL cholesterol levels of 100 mg/dl, three were already on LDL apheresis before the PCSK9 inhibitor treatment, while three were referred to LDL apheresis treatment. Adverse events were reported in two out of 18 patients on evolocumab: one presented with flu-like syndrome and the other reported episodes of mild difficulty in maintaining concentration. Conclusions: PCSK9 inhibitors represent a novel therapeutic tool for patients with familial hypercholesterolemia who are intolerant to statins. However, more data are needed before cleaning up the old therapeutic armamentarium, such as LDL apheresis, which is likely to preserve its valuable role also in the new lipid-lowering era.

11 October 2018 in Therapeutic Apheresis and Dialysis
Verified
Journal Article
Closed access
PDF file
FSFrancesco Sbrana
Francesco Sbrana
FBFederico Bigazzi
Federico Bigazzi
BPBeatrice Dal Pino
Beatrice Dal Pino
MTMaddalena Toma
Maddalena Toma
ARAndrea Ripoli
Andrea Ripoli
TSTiziana Sampietro
Tiziana Sampietro